Skip to main content

Drug Interactions between oxidronate and tiludronate

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tiludronate oxidronate

Applies to: tiludronate and oxidronate

MONITOR: Administration of technetium (Tc 99m) oxidronate after chelating agents, diphosphonates, tetracyclines, or iron containing drugs may reduce the quality of the scintigraphic procedure by decreasing the accumulation of Tc 99m oxidronate in skeletal bone. The exact mechanism of the interaction is unknown; however, it may be related to the effects of the interacting drugs on bone homeostasis.

MANAGEMENT: Proceed with caution if chelating agents, diphosphonates, tetracyclines, and iron-containing drugs are used prior to technetium (Tc 99m) oxidronate. The quality of the resulting imaging may be reduced.

References (7)
  1. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  2. (2018) "Product Information. TechneScan HDP (oxidronate)." Curium Pharmaceuticals
  3. (2023) "Product Information. Technescan HDP (oxidronate)." Landauer Radiopharmaceuticals Pty Ltd
  4. (2021) "Product Information. HDP (Radpharm) (oxidronate)." Global Medical Solutions Pty Limited t/a Radpharm Scientific
  5. (2023) "Product Information. Technescan HDP Kit (oxidronate)." Curium Pharma UK Ltd
  6. Warner AJ, Hathaway-Schrader JD, Lubker R, Davies C, Novince CM (2023) Tetracyclines and bone: unclear actions with potentially lasting effects. https://www.sciencedirect.com/science/article/abs/pii/S8756328222000539
  7. Balogh E, Paragh G, Jeney V (2023) Influence of iron on bone homeostasis. https://www.mdpi.com/1424-8247/11/4/107

Drug and food interactions

Moderate

tiludronate food

Applies to: tiludronate

ADJUST DOSING INTERVAL: Food significantly decreases the bioavailability of tiludronate. The manufacturer reports up to a 90% decrease in bioavailability when administered with or 2 hours after a standard breakfast. Clinical efficacy, however, was demonstrated when tiludronate was taken 2 hours before or after meals.

MANAGEMENT: Tiludronate should be administered with 6 to 8 ounces of plain water at least 2 hours before or 2 hours after food.

References (1)
  1. "Product Information. Skelid (tiludronate)." Sanofi Winthrop Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer